Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Interest Expenses (2016 - 2017)

CytomX Therapeutics' Interest Expenses history spans 4 years, with the latest figure at $206000.0 for Q1 2017.

  • For Q1 2017, Interest Expenses fell 41.64% year-over-year to $206000.0; the TTM value through Dec 2017 reached $206000.0, down 87.8%, while the annual FY2016 figure was $1.7 million, 2.48% down from the prior year.
  • Interest Expenses reached $206000.0 in Q1 2017 per CTMX's latest filing, down from $389000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $718000.0 in Q3 2015 to a low of $109000.0 in Q4 2014.
  • Average Interest Expenses over 4 years is $350272.7, with a median of $376000.0 recorded in 2015.
  • Peak YoY movement for Interest Expenses: soared 513.68% in 2015, then tumbled 41.64% in 2017.
  • A 4-year view of Interest Expenses shows it stood at $109000.0 in 2014, then soared by 244.95% to $376000.0 in 2015, then rose by 3.46% to $389000.0 in 2016, then crashed by 47.04% to $206000.0 in 2017.
  • Per Business Quant, the three most recent readings for CTMX's Interest Expenses are $206000.0 (Q1 2017), $389000.0 (Q4 2016), and $482000.0 (Q3 2016).